MPH Stock Discussion
Medicure Inc. Description
Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company's primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company's United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD). The Company has completed Phase IIa stage of development for TARDOXAL. The Company is also developing Transdermal AGGRASTAT, a cure for acute cardiology. Transdermal AGGRASTAT is in preclinical-stage of development.
Industry: Biotechnology
Keywords: Chemistry Marketing Medicine Pharma Pharmaceutical Clinic Drug Skin Biopharmaceutical Organ Systems Pharmaceutical Industry Disorders Cardiology Neurological Disorders
Recent Comments
- TraderMike on Canadian Depositary Receipts
- Cos3 on Canadian Depositary Receipts
- TraderMike on Canadian Depositary Receipts
- TraderMike on Canadian Depositary Receipts
- Cos3 on Canadian Depositary Receipts
From the Blog
Popular Now
Featured Articles